A cohort study of over 15,000 US adults found that the lifetime risk of developing dementia from ages 55 to 95 is 42%, with the highest risk in APOE ε4 carriers, women and Black adults, and projected that approximately 1 million US adults will develop dementia annually by 2060.

With the Declaration of Helsinki now mandating community engagement, Nature Medicine asks three winners of the Nature Awards for Inclusive Health Research to share their tips.

Studies from wearables show that even small doses of physical activity provide health benefits; guidelines should be updated to reflect this.

In a game-changing development for malaria vaccines, single-dose immunization with a genetically weakened whole malaria parasite vaccine achieved an unprecedented 90% protection.

In an analysis of long-term safety events in 783 patients treated with T cell therapy in 38 trials, 2.3% of patients developed second primary malignancies, and vector integration analyses revealed no pathological insertions.

A finger-based brain–computer interface was developed for a person with tetraplegia to allow him to fly a virtual quadcopter, an innovation that can lead to improved social connectedness, recreation and a sense of enablement.

An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other antihyperglycemic medications, such as sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors.

A comprehensive longitudinal analysis of individuals with preclinical Huntington’s disease identifies biomarkers of neurodegeneration and somatic expansion in blood DNA, detectable years before symptom onset.

In this phase 2 basket trial, patients with heavily pretreated HER2-mutated metastatic breast cancer received the small-molecule HER2 inhibitor tucatinib and anti-HER2 trastuzumab, leading to encouraging clinical response rates.

This flagship study from the European Solve-Rare Diseases Consortium presents a diagnostic framework including bioinformatic analysis of clinical, pedigree and genomic data coupled with expert panel review, leading to 500 new diagnoses in a cohort of 6,000 families with suspected rare diseases.

A study detected hidden cancers in almost half of all pregnant people who were referred for cancer screening following an abnormal or unreportable prenatal blood test result.

Scientists can learn the power of storytelling and coalition-building from patient advocates.

According to preclinical studies and a retrospective clinical analysis, the menstrual cycle may influence the breast cancer response to neoadjuvant chemotherapy — suggesting that treatment could be timed for optimal outcomes.